CytoMed Therapeutics shares surge 22.37% premarket on advancements in cell therapies and strategic partnerships.

CytoMed Therapeutics surged 22.37% in premarket trading following a report highlighting its advancements in cell therapies, strategic partnerships, and financial stability. The article emphasized the company’s progress in Natural Killer cell therapy, collaborations with Enterprise Singapore, and a leverage ratio of 1.1, signaling prudent financial management. These developments, coupled with a $10M asset base and $853,000 in recent revenues, reinforced investor confidence in its sustainable growth trajectory. The market reaction aligns with the news, which underscores innovation in therapy pipelines and strategic expansion plans.